At ACM Biolabs we are focused on developing novel vaccines and antibodies using our proprietary artificial cell membrane ("ACM") technology. We are able to incorporate functional, folded membrane proteins into the artificial cell membranes which keep them stable, allowing them to induce a strong immune reaction. We have demonstrated efficacy via both injected and oral dosages using synthesized membrane proteins and have a growing pipeline of vaccines and antibodies.
The company is headquartered in Singapore, and has been operational since 2013.
Dr. Madhavan Nallani
Founder & CEO
Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering and also at Nanyang Technological University).
Dr. Peter Moran
Previously co-founded Singular ID, a successful Singapore technology company which was acquired by one of the world’s largest pharmaceutical packaging companies.
Dr. Erich Erber
Founder the Erber Group, an Austrian animal nutrition company, which consists of more than 50 affiliates in all continents. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.
Erich is the key investor representative on ACM Biolabs' Board of Directors.
INTRODUCING SOME OF OUR TECHNICAL STAFF
Dr. Fabien Décaillot
PhD, Université Louis Pasteur de Strasbourg in France. He did postdoctoral research at Mount Sinai School of Medicine and Rockefeller University both in the USA. He then joined the Antibody Discovery platform of Singapore Immunology Network (SIgN/ A*Star).
Dr. Nandini Venkatesan
PhD , University of Madras, India. She did her post-doctoral research at the Vaccine R and D Centre, NHRI, Taiwan and at The Genetics and Genomics Division at School of Biological Sciences, NTU Singapore specialising in Cancer Biology , Epigenetics and Post-translational modifications.
Dr. Srinivasa Reddy Mothe
PhD in synthetic Organic and Medicinal Chemistry from Nanyang Technological University, Singapore. Previously he worked for Albany Molecular Research Inc. (Singapore), GVK Bio and Dr. Reddy’s Laboratories (India) in drug discovery and CRO based programmes.
Dr. Alexandra Alvarez Fernández
After PhD at Radboud University Nijmegen (The Netherlands) she joined ENCAPSON B.V. (The Netherlands). Then she did post-doctoral research at Nanyang Technological University, Singapore.
Dr. Kelvin Yong
PhD, in Biochemistry from University of Melbourne, Australia. His specialty is membrane proteins including difficult targets such as GPCRs.
Dr. Tom Cornell
PhD, King’s College London, UK. He did postdoctoral research at Nanyang Technological University, Singapore
ACM Biolabs is backed by government bodies, investment companies and strategic corporate investors such as: San Pacific an investment group associated with the Erber Group, an Austrian Animal Healthcare multinational; Nagase, a Japanese multinational with diverse business interests, and; NTUitive, the innovation and enterprise company of the Nanyang Technological University.